Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2014, Article ID 967073, 6 pages
http://dx.doi.org/10.1155/2014/967073
Review Article

The Effect on Treatment Adherence of Administering Drugs as Fixed-Dose Combinations versus as Separate Pills: Systematic Review and Meta-Analysis

1Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, Amsterdam, The Netherlands
2Department of Medical Psychology (J3-219-1), Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Received 15 May 2014; Accepted 19 August 2014; Published 4 September 2014

Academic Editor: David Katzenstein

Copyright © 2014 Katy A. van Galen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Mannheimer, G. Friedland, J. Matts, C. Child, and M. Chesney, “The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials,” Clinical Infectious Diseases, vol. 34, no. 8, pp. 1115–1121, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. V. D. Lima, R. Harrigan, D. R. Bangsberg et al., “The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time,” Journal of Acquired Immune Deficiency Syndromes, vol. 50, no. 5, pp. 529–536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. T. R. Glass, M. Battegay, M. Cavassini et al., “Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: swiss HIV cohort study,” Journal of Acquired Immune Deficiency Syndromes, vol. 54, no. 2, pp. 197–203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Protopopescu, F. Raffi, P. Roux et al., “Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data,” Journal of Antimicrobial Chemotherapy, vol. 64, no. 3, pp. 599–606, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Lazo, S. J. Gange, T. E. Wilson et al., “Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women,” Clinical Infectious Diseases, vol. 45, no. 10, pp. 1377–1385, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Ammassari, M. P. Trotta, R. Murri et al., “Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature,” Journal of Acquired Immune Deficiency Syndromes, vol. 31, supplement 3, pp. S123–S127, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. V. E. Stone, J. Jordan, J. Tolson, R. Miller, and T. Pilon, “Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence,” Journal of Acquired Immune Deficiency Syndromes, vol. 36, no. 3, pp. 808–816, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. J. B. Nachega, M. J. Mugavero, M. Zeier, M. Vitória, and J. E. Gallant, “Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs,” Patient Preference and Adherence, vol. 5, pp. 357–367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J.-J. Parienti, D. R. Bangsberg, R. Verdon, and E. M. Gardner, “Better adherence with once-daily antiretroviral regimens: a meta-analysis,” Clinical Infectious Diseases, vol. 48, no. 4, pp. 484–488, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Gazzard, C. Moecklinghoff, and A. Hill, “New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom,” ClinicoEconomics and Outcomes Research, vol. 4, no. 1, pp. 193–200, 2012. View at Google Scholar · View at Scopus
  11. M. Stoll, C. Kollan, F. Bergmann et al., “Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv Cohort,” PLoS ONE, vol. 6, no. 9, Article ID e23946, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. G. L. Colombo, S. di Matteo, and F. Maggiolo, “Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen,” ClinicoEconomics and Outcomes Research, vol. 5, no. 1, pp. 59–68, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. R. P. Walensky, P. E. Sax, Y. M. Nakamura et al., “Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States,” Annals of Internal Medicine, vol. 158, no. 2, pp. 84–92, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. J. M. Llibre, J. R. Arribas, P. Domingo et al., “Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy,” AIDS, vol. 25, no. 14, pp. 1683–1690, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. J. J. Eron, E. S. Yetzer, and P. J. Ruane, “Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection,” AIDS, vol. 14, no. 6, pp. 671–681, 2000. View at Publisher · View at Google Scholar
  16. N. Sosa, C. Hill-Zabala, E. DeJesus et al., “Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL),” Journal of Acquired Immune Deficiency Syndromes, vol. 40, no. 4, pp. 422–427, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. L. J. Geiter, R. J. O'Brien, D. L. Combs, and D. E. Snider Jr., “United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide,” Tubercle, vol. 68, no. 2, pp. 41–46, 1987. View at Publisher · View at Google Scholar · View at Scopus
  18. W.-J. Su and R.-P. Perng, “Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up,” International Journal of Tuberculosis and Lung Disease, vol. 6, no. 11, pp. 1029–1032, 2002. View at Google Scholar · View at Scopus
  19. Research Committee of the Tuberculosis Association of India, “Fifth tuberculosis association of India: short course chemotherapy trial,” Indian Journal of Tuberculosis, vol. 36, no. 2, pp. 95–101, 1989. View at Google Scholar
  20. J. Asplund, M. Danielson, and P. Ohman, “Patients compliance in hypertension—the importance of number of tablets,” British Journal of Clinical Pharmacology, vol. 17, no. 5, pp. 547–552, 1984. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Bangalore, G. Kamalakkannan, S. Parkar, and F. H. Messerli, “Fixed-dose combinations improve medication compliance: a meta-analysis,” The American Journal of Medicine, vol. 120, no. 8, pp. 713–719, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. J. P. A. Ioannidis, A.-B. Haidich, M. Pappa et al., “Comparison of evidence of treatment effects in randomized and nonrandomized studies,” The Journal of the American Medical Association, vol. 286, no. 7, pp. 821–830, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. B. C. Reeves, J. J. Deeks, J. P. T. Higgins, and G. A. Wells, “Including non-randomized studies,” in Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, J. P. T. Higgins and S. Green, Eds., chapter 13, 2011. View at Google Scholar
  24. M. Airoldi, M. Zaccarelli, L. Bisi et al., “One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects,” Patient Preference and Adherence, vol. 4, pp. 115–125, 2010. View at Google Scholar · View at Scopus
  25. F. Engsig, J. Gerstoft, M. Helleberg, G. Kronborg, L. Mathiesen, and N. Obel, “Virologica l response in patients who for economic reasons were changed from Atripla to a multi-tablet cART regimen,” in Proceedings of the 20th Conference on Retroviruses and Opportunistic Infections (CROI '13), Atlanta, Ga, USA, March 2013, Abstract 579.
  26. G. A. Rao, S. S. Sutton, J. Hardin et al., “Impact of highly active antiretroviral therapy regimen on adherence and risk of hospitalization in veterans with HIV/AIDS,” in Proceedings of the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC '13), Denver, Colo, USA, September 2013, Abstract H-1464.
  27. C. J. Cohen, J. L. Meyers, and K. L. Davis, “Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US Medicaid population with HIV,” BMJ Open, vol. 3, Article ID e003028, 2013. View at Google Scholar
  28. S. Kapadia, R. Grant, and S. Hodder, “Virologic response better with single tablet fixed dose antiretroviral regimens compared with multiple tablet regimens in an urban population of HIV-infected persons,” in Proceedings of the IDWeek, Advancing Science, Improving Care, Abstract 168, San Francisco, Calif, USA, October 2013.
  29. A. Buscher, C. Hartman, M. A. Kallen, and T. P. Giordano, “Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naïve HIV patients,” International Journal of STD and AIDS, vol. 23, no. 5, pp. 351–355, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. J. A. Bartlett, R. DeMasi, J. Quinn, C. Moxham, and F. Rousseau, “Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults,” AIDS, vol. 15, no. 11, pp. 1369–1377, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. J. B. Nachega, J. J. Parienti, O. A. Uthman et al., “Lower pill burden and once-daily antiretroviral treatment regimens for hiv infection: a meta-analysis of randomized controlled trials,” Clinical Infectious Diseases, vol. 58, pp. 1297–1307, 2014. View at Google Scholar